Literature DB >> 21596726

Serum phenytoin concentrations in paediatric patients following intravenous loading.

Daniel B Hawcutt1, Sunil Sampath, Alison Timmis, Veronica Newland, Paul Newland, Richard Appleton.   

Abstract

Phenytoin is used to treat acute tonic-clonic seizures in children who have not responded to a benzodiazepine. In the UK, the loading dose of phenytoin is 18 mg/kg. There is limited evidence on whether this loading dose will achieve the desired levels in paediatric patients. Intravenous loading doses of phenytoin were retrospectively and prospectively audited over 19 months. Doses were normalised for weight and compared with the serum phenytoin concentrations. Errors in dose calculations and adverse events were recorded. Serum phenytoin concentrations were measured on 31 occasions in 27 children (24 retrospective and 10 prospective) between 60 and 180 (median, 153) min after completion of the loading dose. Serum phenytoin concentrations were within the therapeutic range (10-20 μg/ml) on 24 occasions. No errors in dose calculations or adverse effects were identified. A phenytoin loading dose of 18 mg/kg gave serum concentrations within the recommended therapeutic range in most children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596726     DOI: 10.1136/adc.2011.215269

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  3 in total

1.  Consequences of Phenytoin Exposure on Hepatic Cytochrome P450 Expression during Postnatal Liver Maturation in Mice.

Authors:  Stephanie C Piekos; Liming Chen; Pengcheng Wang; Jian Shi; Sharon Yaqoob; Hao-Jie Zhu; Xiaochao Ma; Xiao-Bo Zhong
Journal:  Drug Metab Dispos       Date:  2018-06-08       Impact factor: 3.922

Review 2.  Cardiovascular adverse effects of phenytoin.

Authors:  B Guldiken; J Rémi; Soheyl Noachtar
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

3.  Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development.

Authors:  Patrick A Forcelli; Megan J Janssen; Stefano Vicini; Karen Gale
Journal:  Ann Neurol       Date:  2012-05-11       Impact factor: 10.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.